(-0.01%) 5 307.50 points
(0.04%) 40 160 points
(-0.01%) 18 502 points
(1.72%) $82.75
(0.64%) $1.729
(0.78%) $2 230.00
(-0.14%) $24.72
(0.38%) $913.20
(0.33%) $0.926
(0.58%) $10.83
(0.09%) $0.792
(-0.03%) $92.41
@ $1.160
Issued: 14 Feb 2024 @ 09:35
Return: 28.45%
Previous signal: Feb 13 - 09:30
Previous signal:
Return: 0.00 %
Live Chart Being Loaded With Signals
Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases...
Stats | |
---|---|
Today's Volume | 656 330 |
Average Volume | 1.12M |
Market Cap | 261.31M |
EPS | $0 ( 2024-03-05 ) |
Next earnings date | ( $-0.0300 ) 2024-05-07 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -10.64 |
ATR14 | $0.00300 (0.20%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-02-28 | Schorno Dean L | Buy | 78 500 | Employee Stock Option (right to buy) |
2024-02-28 | Schorno Dean L | Buy | 62 500 | Employee Stock Option (right to buy) |
2024-02-28 | Santos David A | Buy | 80 000 | Employee Stock Option (right to buy) |
2024-02-28 | Santos David A | Buy | 78 500 | Employee Stock Option (right to buy) |
2024-02-28 | Rodriguez Raul R | Buy | 300 000 | Employee Stock Option (right to buy) |
INSIDER POWER |
---|
92.88 |
Last 99 transactions |
Buy: 9 521 500 | Sell: 304 047 |
Volume Correlation
Rigel Pharmaceuticals Inc Correlation
10 Most Positive Correlations | |
---|---|
CRNC | 0.963 |
ROIV | 0.959 |
NLSP | 0.958 |
MLCO | 0.954 |
MOMO | 0.954 |
FXCO | 0.951 |
CTSO | 0.949 |
APAC | 0.948 |
VRDN | 0.946 |
BRAC | 0.945 |
10 Most Negative Correlations | |
---|---|
GRIN | -0.954 |
PIII | -0.939 |
RIVN | -0.938 |
SNPX | -0.925 |
OP | -0.924 |
SWAV | -0.923 |
ZENV | -0.923 |
LAWS | -0.919 |
NAKD | -0.916 |
ENPH | -0.916 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Rigel Pharmaceuticals Inc Correlation - Currency/Commodity
Rigel Pharmaceuticals Inc Financials
Annual | 2023 |
Revenue: | $116.88M |
Gross Profit: | $109.77M (93.92 %) |
EPS: | $-0.140 |
Q4 | 2023 |
Revenue: | $35.79M |
Gross Profit: | $32.00M (89.41 %) |
EPS: | $0.00420 |
Q3 | 2023 |
Revenue: | $28.13M |
Gross Profit: | $26.87M (95.49 %) |
EPS: | $-0.0326 |
Q2 | 2023 |
Revenue: | $26.89M |
Gross Profit: | $25.81M (96.00 %) |
EPS: | $-0.0380 |
Financial Reports:
No articles found.
Rigel Pharmaceuticals Inc
Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is in phase III clinical trial for the treatment of warm autoimmune hemolytic anemia; phase III clinical trial for the treatment of hospitalized COVID-19 patients; and phase III clinical trial for the treatment of COVID-19. In addition, the company is developing R289, an oral interleukin receptor associated kinase 1/4 inhibitor, which is in phase I clinical trial for autoimmune, inflammatory, and hematology-oncology diseases; and R552, a receptor-interacting serine/threonine-protein kinase 1 inhibitor that has completed phase I clinical trial for autoimmune and inflammatory diseases. It has research and license agreements with AstraZeneca AB for the development and commercialization of R256, an inhaled JAK inhibitor; BerGenBio AS for the development and commercialization of AXL inhibitors in oncology; and Daiichi Sankyo to develop murine double minute 2 inhibitors for solid and hematological malignancies, as well as license and supply agreement with Kissei Pharmaceutical Co., Ltd. to develop and commercialize Fostamatinib. The company also has a license agreement and strategic collaboration with Eli Lilly and Company to co-develop and commercialize R552 for various indications, including autoimmune and inflammatory diseases, as well as other non-central nervous system (non-CNS) disease development candidates. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators